Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06710509 · ClinicalTrials.gov registry record · NA
Patient Reminders Optimizing Mail-in Prevention Testing for Colorectal Cancer
A NA study of Colon Cancer Screening, sponsored by Emily Rosenzweig.
- Completed
- Registry status
- NA
- Development phase
- 2,106
- Enrollment target
- 1
- Study location
NCT06710509: Completed NA study of Colon Cancer Screening, sponsored by Emily Rosenzweig.
NCT06710509 is a NA study of Colon Cancer Screening that has completed, run by Emily Rosenzweig. The registered enrollment target is 2,106 participants, above the 82-participant average among 4 other Colon Cancer Screening trials with a reported enrollment target (2468% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06710509, a NA study of Colon Cancer Screening, has completed, sponsored by Emily Rosenzweig.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,106 participants
- Enrollment target
- 1
- Study location
Study Summary
Screening is an important tool for early colorectal cancer detection, and the most recent evidence suggests that early detection significantly improves survival rates. Current medical guidelines recommend that all people aged 45 to 75 be screened regularly. However, actual rates of screening in the United States are much lower than this. Colonoscopy is the gold standard in colon cancer screening, serving as both screening and prevention. However there are many barriers to colonoscopy uptake, including lack of awareness, patient reticence, scheduling complexity, and market variation in access. Stool testing is a valuable alternative to colonoscopy for low-risk patients. Exact Sciences is the company that makes Cologuard, which is the current best-in-class stool testing for colon cancer screening. Despite being a convenient at-home screening option, patient engagement with screening via stool testing has room for improvement. Over 40% of Ascension patients who have a stool testing order placed for them never return the screening kit in the mail. A large body of research demonstrates that interventions informed by behavioral science can support patients in engaging in a variety of preventative health behaviors. Personalized nudges have proven to be among the most effective types of interventions, along with interventions aimed at helping patients overcome barriers to screening. We aim to test whether behavioral nudges can increase stool testing kit return rates.
Primary Outcome
Percentage of patients who have Cologuard stool testing lab results returned 4 weeks after receiving the intervention
Conditions Studied
Interventions
- BEHAVIORAL Three Messaging Nudges
Study Locations (1)
Missouri
- Ascension Health - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,106 participants |
| Start Date | 2024-12-05 |
| Est. Completion | 2025-02-26 |
| Phase | NA |
What the finished NCT06710509 record still lists
NCT06710509 is an interventional study that assigns participants to a tested intervention. Its 2,106 participants enrollment target places it among the larger protocols in the corpus, above the 82-participant average among 4 other Colon Cancer Screening trials with a reported enrollment target (2468% higher).
The record links to 1 condition, with Colon Cancer Screening appearing as the primary indexed condition, and to 1 intervention - of which Three Messaging Nudges is the first listed.
NCT06710509 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT06710509 about?
NCT06710509 is a clinical study titled "Patient Reminders Optimizing Mail-in Prevention Testing for Colorectal Cancer". Screening is an important tool for early colorectal cancer detection, and the most recent evidence suggests that early detection significantly improves survival rates. Current medical guidelines recommend that all people aged 45 to 75 be screened regularly. However, actual rates of screening in the ...
What is the current status of trial NCT06710509?
This trial is currently completed. It is a NA study. The enrollment target is 2,106 participants. The study started on 2024-12-05. Estimated completion is 2025-02-26.
What conditions does trial NCT06710509 study?
This clinical trial studies the following conditions: Colon Cancer Screening.
What interventions are being tested in trial NCT06710509?
The interventions under investigation include: Three Messaging Nudges (BEHAVIORAL).
Who is sponsoring clinical trial NCT06710509?
This trial is sponsored by Emily Rosenzweig, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06710509 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colon Cancer Screening
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Using Social Networks to Encourage Three Peers to Complete Screening for Colorectal Cancer
ACTIVE NOT RECRUITING · NA
-
Johns Hopkins Interactive eGuide to Colonoscopy and Ipad Office Education to Improve Colonoscopy
COMPLETED · NA
-
Comparison of Colon Adenoma Detection Rate Using Two Distal Colonoscope Attachments
COMPLETED · NA
-
Colonoscopy Bowel Prep Comparison Among Diabetic Patients
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05967273 · 2,106 participants · NA
CirrhosisRx CDS System
- NCT04649242 · 2,100 participants · Phase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
- NCT05206331 · 2,100 participants · Phase 4
CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study
- NCT05270499 · 2,100 participants
Aveir VR Real-World Evidence Post-Approval Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI